Skip to content
lifestyle.successfuldaily.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Compass Therapeutics
Compass Therapeutics to Participate in Upcoming May Investor Events
May 23, 2026
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
May 20, 2026
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
May 20, 2026
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
May 16, 2026
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
March 5, 2026